# Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

> **NCT03629873** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 69 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Mantle Cell Lymphoma
- Peripheral T Cell Lymphoma
- Double-hit Lymphoma

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03629873
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629873, "Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03629873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*